Advancing the Future of Tricuspid Care: Reflections from PCR London Valves 2025
The 2025 edition of PCR London Valves brought together the global cardiovascular community for three days of collaboration, education, and innovation focused on advancing structural heart therapies. For the P&F Products & Features team, it was an inspiring opportunity to share new clinical evidence, connect with physicians at the forefront of tricuspid intervention, and continue shaping the future of bicaval valve therapy.
A Shared Mission: Expanding Options for High-Risk Patients
At the heart of P&Fโs work is a commitment to patients with limited treatment options. The TricValveยฎ Transcatheter Bicaval System* was developed specifically for those with severe tricuspid regurgitation who are not candidates for surgery or leaflet-based transcatheter repair. By addressing caval reflux without touching the native tricuspid valve, TricValve can provide a less invasive path forward โ one that continues to show promise across a growing body of real-world data.
Key Highlights from the Meeting
Throughout PCR London Valves, the discussion around tricuspid disease reflected a rapidly evolving landscape in which bicaval therapy is gaining attention as an essential complement to leaflet-based solutions.
Some of the most engaging moments included:
- Presentation of new data from the TricBicaval Registry and TRICAV-I experience, highlighting improved outcomes and sustained symptom relief in high-risk patients.
- Educational discussions around patient selection and right ventricular function assessment โ key factors in optimizing procedural success.
- Clinical collaboration with physicians sharing firsthand experiences on SVCโIVC navigation, access strategies, and long-term patient management.
These exchanges underscored the importance of a personalized, anatomy-driven approach to treating tricuspid regurgitation โ one that considers both patient complexity and device adaptability.
Connecting with the Global Heart Team
Our booth at PCR London Valves served as a space for meaningful conversations with interventional cardiologists, imaging specialists, and heart team members from across the globe. From live case discussions to hands-on exploration of the TricValve system, it was encouraging to see the growing curiosity and confidence in bicaval valve therapy.
Each discussion reaffirmed the value of collaboration โ that the best patient outcomes arise when shared expertise and innovation come together.
The Future of Tricuspid Valve Treatments
As we reflect on PCR London Valves 2025, P&F is motivated by the continued momentum toward a more comprehensive tricuspid treatment ecosystem. The expanding clinical experience with TricValve reinforces its role in addressing a patient population often left without options.
We remain dedicated to supporting the global physician community through ongoing education, research, and collaboration โ because every advancement brings us closer to improving quality of life for patients with tricuspid disease.
Thank You to PCR London Valves
A sincere thank-you to the organizers of PCR London Valves, the physicians who shared their knowledge, and all who visited the P&F booth to engage with our team. Together, we are redefining whatโs possible in tricuspid care.
